Eton Pharmaceuticals (ETON) Gross Margin (2019 - 2025)

Eton Pharmaceuticals has disclosed Gross Margin across 7 years of filings, most recently posting 61.56% for Q4 2025.

• Gross Margin for Q4 2025 came in at 61.56%, up 595.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 66.31% (up 630.0% YoY), and the FY2025 annual result was 53.46%, down 655.0% from the prior year.
• Gross Margin came in at 61.56% for Q4 2025 at Eton Pharmaceuticals, up from 34.97% in the prior quarter.
• In the past five years, Gross Margin ranged from a high of 552.13% in Q1 2025 to a low of 12.18% in Q4 2023.
• The 5-year median for Gross Margin is 62.77% (2024), against an average of 87.65%.
• Across the five-year window, Gross Margin tumbled 720611 bps in 2021 and surged 48927 bps in 2025, its largest moves.
• Eton Pharmaceuticals' Gross Margin stood at 93.89% in 2021, then slipped by 20 bps to 74.84% in 2022, then slumped by 84 bps to 12.18% in 2023, then surged by 356 bps to 55.6% in 2024, then climbed by 11 bps to 61.56% in 2025.
• The last three Gross Margin figures came in at 61.56% (Q4 2025), 34.97% (Q3 2025), and 63.0% (Q2 2025), per Business Quant data.